CRISPR Therapeutics AG (CRSP)
51.14
-2.46
(-4.60%)
USD |
NASDAQ |
May 10, 16:00
51.25
+0.12
(+0.22%)
After-Hours: 19:59
CRISPR Therapeutics Enterprise Value: 2.856B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 2.856B |
| May 08, 2024 | 2.830B |
| May 07, 2024 | 3.020B |
| May 06, 2024 | 3.150B |
| May 03, 2024 | 3.050B |
| May 02, 2024 | 2.981B |
| May 01, 2024 | 2.874B |
| April 30, 2024 | 2.804B |
| April 29, 2024 | 2.960B |
| April 26, 2024 | 2.882B |
| April 25, 2024 | 2.867B |
| April 24, 2024 | 3.030B |
| April 23, 2024 | 3.095B |
| April 22, 2024 | 3.031B |
| April 19, 2024 | 2.979B |
| April 18, 2024 | 3.073B |
| April 17, 2024 | 3.022B |
| April 16, 2024 | 3.226B |
| April 15, 2024 | 3.291B |
| April 12, 2024 | 3.456B |
| April 11, 2024 | 3.646B |
| April 10, 2024 | 3.547B |
| April 09, 2024 | 3.840B |
| April 08, 2024 | 3.746B |
| April 05, 2024 | 3.637B |
| Date | Value |
|---|---|
| April 04, 2024 | 3.820B |
| April 03, 2024 | 3.781B |
| April 02, 2024 | 3.817B |
| April 01, 2024 | 4.084B |
| March 28, 2024 | 4.083B |
| March 27, 2024 | 4.252B |
| March 26, 2024 | 4.321B |
| March 25, 2024 | 4.330B |
| March 22, 2024 | 4.375B |
| March 21, 2024 | 4.620B |
| March 20, 2024 | 4.488B |
| March 19, 2024 | 4.405B |
| March 18, 2024 | 4.363B |
| March 15, 2024 | 4.489B |
| March 14, 2024 | 4.087B |
| March 13, 2024 | 4.309B |
| March 12, 2024 | 4.351B |
| March 11, 2024 | 4.473B |
| March 08, 2024 | 4.642B |
| March 07, 2024 | 4.678B |
| March 06, 2024 | 4.795B |
| March 05, 2024 | 4.808B |
| March 04, 2024 | 4.868B |
| March 01, 2024 | 5.029B |
| February 29, 2024 | 5.067B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.107B
Minimum
Mar 16 2020
13.83B
Maximum
Jan 14 2021
3.836B
Average
2.980B
Median
Jun 15 2020
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 97.95B |
| Intellia Therapeutics Inc | 1.478B |
| Novartis AG | 220.39B |
| AC Immune SA | 109.73M |
| Addex Therapeutics Ltd | 4.963M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 89.35M |
| Revenue (Quarterly) | 200.00M |
| Total Expenses (Quarterly) | 130.42M |
| EPS Diluted (Quarterly) | 1.13 |
| Gross Profit Margin (Quarterly) | 90.00% |
| Profit Margin (Quarterly) | 44.67% |
| Earnings Yield | -3.77% |
| Normalized Earnings Yield | -3.774 |